Should we pursue horizontal (pipeline acquisition) or vertical (supply chain) partnerships to enhance our GLP-1 competitiveness
Mounjaro contains the same active ingredient as Zepbound but is not approved for weight loss
If youre not losing weight, here are a couple of common reasons why that might be happening: Dosage Issues A common reason for not losing weight on semaglutide is not being on a high enough dosage
In addition to quieting that food noise, these types of weight loss medications can actually reduce heart disease, that might be independent of weight loss, in addition to improvements in heart function and functional status in individuals with heart failure. The medication is also currently being studied for how it can target symptoms of kidney disease and Alzheimers
Tirzepatide, administered as a weekly subcutaneous injection, and additional dual GLP-1/GIP receptor agonists that could eventually be developed in the future seem to be a promising furthest advance for the management of several cardiometabolic settings
Retatrutide is an investigational molecule that is legally available only to participants in Lilly's clinical trials
